Sentences with phrase «for ejection fraction»

On those echo tests, ask the doctor about your results for ejection fraction (or EF).

Not exact matches

The rationale for using spironolactone - an inexpensive, generic, medication - stems from the pioneering research of Bertram Pitt, MD, University of Michigan School of Medicine, who showed the benefit of this class of drugs in patients with heart failure and reduced ejection fraction, and who also served as chair of the TOPCAT Steering Committee.
The standard test for risk assessment in relation to life - threatening cardiac rhythm disturbances is currently the left ventricular ejection fraction, which represents a measure of the heart's function and measures the volume of the beat in relation to the overall volume of blood in the ventricle.
Participants with symptomatic heart failure and a left ventricular ejection fraction of 45 percent or more (normal or near normal contractions) were randomized to receive either spironolactone (15 to 45 milligrams daily) or matching placebo, and were followed for an average of nearly 3.3 years.
The 10 - year Warfarin and Aspirin for Reduced Cardiac Ejection Fraction (WARCEF) trial is the largest randomized, double - blind comparison of aspirin and warfarin (also known by its brand name Coumadin) for heart failure, following 2,305 heart failure patients whose heart muscle pumps less oxygen - rich blood into the body, known as reduced ejection fraction, at 168 study sites in 11 countries on three conEjection Fraction (WARCEF) trial is the largest randomized, double - blind comparison of aspirin and warfarin (also known by its brand name Coumadin) for heart failure, following 2,305 heart failure patients whose heart muscle pumps less oxygen - rich blood into the body, known as reduced ejection fraction, at 168 study sites in 11 countries on three conFraction (WARCEF) trial is the largest randomized, double - blind comparison of aspirin and warfarin (also known by its brand name Coumadin) for heart failure, following 2,305 heart failure patients whose heart muscle pumps less oxygen - rich blood into the body, known as reduced ejection fraction, at 168 study sites in 11 countries on three conejection fraction, at 168 study sites in 11 countries on three confraction, at 168 study sites in 11 countries on three continents.
• Patients must have adequate coagulation (international normalized ratio (INR) or prothrombin time (PT), partial thromboplastin time (PTT) ≤ 1.5 times ULN) • Adequate liver function (total bilirubin ≤ 1.5 times the ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN Exclusion Criteria: • Presence of active / uncontrolled central nervous system involvement • History of clinically significant cardiac disease; uncontrolled hypertension • Left ventricular ejection fraction (LVEF) < 45 % • Allogeneic stem cell transplant within 100 days before first dose of study drug • Known history of human immunodeficiency virus (HIV) infection • Chronic or active hepatitis B or C, requiring antiviral therapy • Evidence of history of bleeding disorder, dialysis, or coexisting cancer that is distinct in primary site or histology from the cancer evaluated in this study • Serious, uncontrolled infection • Unresolved chronic toxicity > grade 1 from prior therapy • Use of strong CYP3A4 inhibitors or strong inducers within 7 days prior to the start of study treatment and for the duration of the study
Inclusion Criteria: • Availability of tumor tissue for mesothelin expression testing • Histologically - confirmed, mesothelin - expressing metastatic or advanced non-metastatic disease (tumour type specific inclusion criteria) • At least one measurable lesion according to either Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or International Thymic Malignancy Interest Group (ITMIG) modified RECIST 1.1 as applicable • Adequate bone marrow, liver, renal and coagulation function • Left ventricular ejection fraction (LVEF) ≥ 50 % of the lower limit of normal (LLN) according to local institutional ranges • Eastern Cooperative Oncology Group (ECOG) 0 or 1 Exclusion Criteria: • More than one prior anti - tubulin / microtubule agent • Corneal epitheliopathy or any eye disorder that may predispose the patients to this condition • Symptomatic Central nervous system (CNS) metastases and / or carcinomatous meningitis • Contraindication to both CT and MRI contrast agents • Active hepatitis B or C infection • Pregnant or breast - feeding patients • Tumor type specific exclusion criteria
Omecamtiv mecarbil is a selective, small - molecule currently being studied in a Phase 3 clinical trial of ~ 8000 patients as a potential treatment for heart failure with reduced ejection fraction in collaboration with Amgen and in partnership with Servier.
Recovery and outcomes were assessed in several ways: MACE (major adverse cardiac events, ranging from hospitalization for chest pain to death), ejection fraction, measured by magnetic resonance imaging, and perfusion or blood flow in the heart, measured by SPECT imaging.
Researchers (Y Omori, T Ohtani, et al), at the Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Japan, developed an animal study to analyze potential new treatments for heart failure — specifically heart failure with preserved ejection fraction (HFpEF) in hypertensive heart disease.
• increased left ventricular ejection fraction (11, 12) • improved exercise tolerance (12, 13, 14) • increased cardiac output (15) • better prognosis for patients with chronic heart failure (16) • lowered markers of oxidative stress (17, 18)
Posted in coronary artery disease (CAD), ejection fraction, heart disease, insurance, life insurance, LVEF Tagged cardiologist normal is normal, echocardiogram, ejection fraction, insurance, life insurance, life insurance underwriter, lipid panel to die for, LVEF, medical test result normal, medical test result not normal enough, mistake that higher EF is better, no actuarial basis, normal range 50 % to 65 %, treadmill stress test, underwriter low normal is almost not normal, underwriters playing doctor
a b c d e f g h i j k l m n o p q r s t u v w x y z